Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.

Cancer letters - 28 Jun 2016

Zhu Guannan, Yi Xiuli, Haferkamp Sebastian, Hesbacher Sonja, Li Chunying, Goebeler Matthias, Gao Tianwen, Houben Roland, Schrama David

Abstract excerpt

Oncogenic triggering of the MAPK pathway in melanocytes results in senescence, and senescence escape is considered as one critical step for melanocytic transformation. In melanoma, induction of a senescent-like state by BRAF-inhibitors (BRAFi) in a fraction of treated cells - instead of killing - contributes to the repression of tumor growth, but may also provide a source for relapse. Here, we demonstrate that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Precursor Protein Secretases
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cellular Senescence

Share to Cyclin-Dependent Kinase 6

Share to Melanocytes

Share to Protease Inhibitors

Share to Receptor, Notch1

Share to Retinoblastoma Protein

Source

Identifiers

PMID: 27000992
DOI: 10.1016/j.canlet.2016.03.028

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.PMID 27000992Read ↗

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated MelanomaSemantic proximity Read ↗

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.Semantic proximity Read ↗

Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cellsSemantic proximity Read ↗

Advances in melanoma senescence and potential clinical application.Semantic proximity Read ↗

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.Semantic proximity Read ↗

C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.Semantic proximity Read ↗

PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.Semantic proximity Read ↗

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.Semantic proximity Read ↗

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cellsSemantic proximity Read ↗

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i> / <i>NRAS</i> StatusSemantic proximity Read ↗

Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescenceSemantic proximity Read ↗

Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.